latest update:
[TrialBase DB]

trial summary · NCT07766187

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma (CODAH Trial)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Intrahepatic Cholangiocarcinoma, sponsored by University of Wisconsin, Madison. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07766187phase PHASE2enrollment 12start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic cholangiocarcinoma (iCCA). Histotripsy is a non-invasive, non-thermal treatment that uses focused ultrasound energy to destroy tumor tissue. 12 people will be enrolled in this study.

Source record: https://clinicaltrials.gov/study/NCT07766187

Facts

registry idNCT07766187
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionIntrahepatic Cholangiocarcinoma
sponsorUniversity of Wisconsin, Madison
sponsor classOTHER
enrollment12
start date2026-11
primary completion2032-08
completion2032-08
results postednot reported

Conditions

  • Intrahepatic Cholangiocarcinoma

Interventions

  • Histotripsy
  • Durvalumab
  • Biopsy

Countries

  • United States

Intervention types: DEVICE, DRUG, PROCEDURE

Work with this record